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Abstract
Purpose Idebenone is a synthetic analogue of ubiquinone
that may be beneficial in the treatment of Friedreich’s
ataxia. Since in previous pharmacokinetic trials only lower
doses were studied, it was the aim of this study to evaluate
the pharmacokinetics of idebenone in higher doses of up to
2,250 mg/day.
Methods In this open, randomized trial, 25 healthy male
subjects received first either a single oral dose of
150 mg or 750 mg of idebenone, then the same dose
given at 8-h intervals for 14 days.
Results Idebenone and its metabolites appeared in the
plasma quickly. Over 99% of parent idebenone was
metabolized, indicating a high first-pass effect. Cmax and
AUC0−t values for parent idebenone and its metabolites
increased in a dose-proportional manner. There was
virtually no accumulation of parent drug or metabolites
following multiple dosing.
Conclusions Idebenone exhibited dose-dependent pharma-
cokinetics in daily doses up to 2,250 mg. In 6/14 subjects,
adverse events of mild to moderate severity were observed.
Keywords Idebenone . Friedreich’s ataxia .
Electron transport . Humans . Pharmacokinetics
Introduction
Friedreich’s ataxia (FA) is the most prevalent autosomal
recessive neurodegenerative disorder, characterized by
disabling limb ataxia, weakness, sensory loss, skeletal
deformities, and hypertrophic cardiomyopathy [1]. FA is
caused by mutations in the FRDA gene located on
chromosome 9q13. The product of the gene is frataxin, a
ubiquitous 18-kDa soluble mitochondrial protein with 210
amino acids. The most frequent mutation is the expansion
of a GAA trinucleotide repeat located within the first intron
of the gene, leading to a deficiency of mitochondrial
frataxin [2]. There is evidence that frataxin is involved in
the assembly of iron-sulfur complexes. Reduced levels of
frataxin diminish the activities of iron-sulfur cluster-
containing enzymes such as complex I and III in the
mitochondrial electron transport chain (ETC), resulting in
decreased oxidative phosphorylation as well as intramito-
chondrial iron accumulation and production of free radicals
in patients with FA [3, 4]. Deficiency of ATP synthesis [5]
and oxidative stress [6] in the pathology of FA have led to
the hypotheses that compounds that support the mitochon-
drial ETC and cellular ATP generation, coupled with
antioxidant qualities, such as idebenone, would offer a
potential treatment for patients with FA [7]. Currently, there
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is no cure for this disease, and treatments are limited to
supportive medical care.
Idebenone [2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-
21,4-benzoquinone; Fig. 1a] is a synthetic analogue of
ubiquinone, a vital cell membrane antioxidant and essen-
tial constituent of the ETC. Suno et al. proposed as early
as 1984 that idebenone inhibits lipid peroxidation and
consequently protects cell membranes and mitochondria
from oxidative damage [8, 9]. Idebenone also interacts
with the ETC, preserving ATP formation and cerebral
metabolism [10]. Due to its ability to support mitochon-
drial energy production and its antioxidant action, idebe-
none was initially evaluated in Japan for the treatment of
cognitive disorders and Alzheimer’s disease [11]. Large
clinical trials showed that idebenone was safe and well
tolerated in these patients [12–14], but lack of improve-
ment in cognitive function led to the termination of
development for this indication. The favorable safety
profile of idebenone and its dual mechanism of action have
led to investigation of its use in other neurodegenerative
diseases with mitochondrial impairment, most notably FA.
Idebenone has been shown to reduce markers of
oxidative DNA damage in patients with FA [6]. Several
open-label studies found that 5 mg kg−1 day−1 of idebenone
reduced cardiac hypertrophy but had no consistent effect on
neurological symptoms at this dose level [15–17]. Other
authors showed that higher doses of idebenone may be
necessary for patients to experience the full clinical benefit
of idebenone treatment, particularly as it relates to improve-
ments in neurological function [16, 18–21]
Information on pharmacokinetics and metabolism of
idebenone is limited, particularly with regard to the
pharmacologically active parent idebenone. Parent idebe-
none is rapidly metabolized through oxidation and side-
chain shortening to inactive metabolites QS10, QS8, QS6,
and QS4 (Fig. 1b) [22]; both parent idebenone and its
metabolites exist either free or conjugated to sulfates and
glucuronides. The analytical methods published to date
were not sensitive enough to reliably measure parent
idebenone, and therefore, only the total amount of
idebenone (parent drug + conjugated idebenone) in plasma
was determined in the past [23]. In a recent study by Di
Prospero et al. [3], safety and pharmacokinetics of high-
dose idebenone in FA patients were investigated. However,
neither plasma levels of parent idebenone nor urine
excretion data of idebenone or its metabolites were
reported. Therefore, the goals of the present study were to
use a newly developed analytical method with greater
sensitivity and specificity for pharmacologically active
parent idebenone to more accurately investigate the
pharmacokinetics and metabolism of idebenone (parent
drug and metabolites) and to evaluate the safety of
idebenone, administered in doses of up to 2,250 mg daily
for 2 weeks, in healthy male subjects.
Methods
Subjects
Healthy Caucasian male subjects aged between 18 and
45 years were eligible for enrollment if they had a body
mass index of 19–29 kg/m2. Subjects with hypertension,
hypotension, a history of alcohol abuse or drug addiction, a
current practice of smoking >10 cigarettes/day, prior
donation of blood within 60 days, prior receipt of blood
products within 1 year, relevant allergy, mental handicap,
legal incapacity, or clinically important psychiatric illness
were excluded. Limited use of paracetamol (acetamino-
phen) was permitted during this study. Use of all other
medications or vitamins was prohibited from 14 days
before the study began through the conclusion of the study.
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Fig. 1 a Structural formula of parent idebenone. b Parent idebenone
is metabolized through side-chain shortening to QS10, QS8, QS6, and
QS4. Idebenone and its metabolites exist free or conjugated (C) to
sulfates and glucuronides
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Ethical conduct of the study
The study was performed at the Department of Clinical
Pharmacology, University Hospital, Basel, Switzerland,
between July 2005 and December 2005. Subjects gave
written informed consent before any study-related activi-
ties were carried out. The clinical study protocols and
written informed consent form were approved by the State
Ethical Committee (Ethische Kommission beider Basel)
and the national drug agency (Swissmedic). The studies
were performed in accordance with the Declaration of
Helsinki, Guidelines on Good Clinical Practice, and
followed the Guidelines of the International Conference
of Harmonization.
Study design
This was an open-label, randomized, parallel-group study
conducted at a single center. Idebenone was administered as
150-mg film-coated tablet [SNT-MC17; Santhera Pharma-
ceuticals (Switzerland)]. Each dose consisted of either a
single 150-mg idebenone tablet orally (group A) or 5×
150-mg idebenone tablets (750 mg) orally (group B). The
dosing schedule was the same for subjects in both groups.
On day 1, each subject received a single idebenone dose
(150 mg or 750 mg) after a continental breakfast that
consisted of 160 g bread, 20 g butter, 25 g jam, 200 ml of
fruit tea or coffee, 50 g whole milk, and 180 g fruit yogurt
(797 kilocalories, 10% protein, 28% fat, 62% carbohy-
drates). After a wash-out period of 7 days, subjects received
idebenone doses three times a day (group A: 450 mg total
daily dose; group B: 2,250 mg total daily dose) at
8-h intervals for 14.3 days. The morning dose was always
given after a continental breakfast.
On both day 1 and day 22, blood samples (5 mL) were
taken before the first administration of idebenone (−15 min)
and 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5,
6, 8, 12, 16, 24, 36, 48, 60, 72, and 96 h thereafter. Samples
were also collected on day 8 (first day of thrice daily
dosing), day 10, day 12, day 14, day 16, day 18, and day
20, always before the morning drug administration.
Samples were taken by an indwelling catheter up to the
16-h sample and by individual venous punctures thereafter.
Each sample was collected into a lithium-heparin-containing
tube (Sarstedt, Nümbrecht, Germany) and was immediately
put on ice and centrifuged at 1,500 g for 10 min at 4°C
within 30 min after sampling. Two aliquots were separated
and stored in polypropylene tubes at −80°C, with a minimum
volume of 1.5 mL of plasma per tube, until plasma level
determinations were carried out.
Urine was collected quantitatively. The urine volume
was measured and an aliquot of approximately 25 mL was
separated and stored in a polypropylene tube at −80°C until
determinations were carried out. Urine samples for phar-
macokinetic assessment were collected immediately before
the first administration of idebenone on day 1 (time 0) and
over 12-h intervals (0–12, 12–24, 24–48, 48–72, and 72–
96 h) thereafter. A final sample was collected over the 8 h
following the final dose of idebenone on day 22.
Safety assessments, including adverse-event monitoring,
vital signs, 12-lead electrocardiograms, and laboratory
values (hematology, serum chemistry, and urinalysis), were
performed during the course of the study.
Analysis of idebenone concentrations
Parent idebenone in plasma Plasma samples were delivered
to a commercial analytical laboratory (Inovalab, Reinach,
Switzerland) in deep-frozen state on dry ice and stored at
about −80°C. After thawing, 10 µL of EDTA (pH 7,
37.7 mg/ml) solution was added to each sample
(0.150 mL) to avoid spontaneous degradation of conju-
gated metabolites to parent idebenone. Thereafter, 300 µL
of internal standard (deuterium-labeled idebenone; idebe-
none-d3 dissolved in absolute methanol) was added. After
centrifugation for at least 45 min at 4°C (1,960 g), the
samples were injected into the triple quadrupole LC-MS/
MS (liquid chromatography-tandem mass spectroscopy)
system (guard column: Phenomenex MAX-RP; 4×
2.0 mm, Brechbühler, Schlieren, Switzerland; main
column: Phenomenex Synergy 4 µ MAX-RP; 2.0×
50 mm, Brechbühler). Two mobile phases [phase A:
H2O+30 mM NH4OAc, pH 4, phase B: MeOH/H2O
100/3 (v/v)+30 mM NH4OAc, pH=4] were used for
elution. Detection was performed after electrospray ioni-
zation (API 4000 from MDS Sciex). For parent idebenone,
the transition m/z 339 to 197 was used. The lower limit of
quantification (LLQ) of parent idebenone was 0.5 ng/mL.
Accuracy and precision were 106.0–107.2% and 4.6–
7.5%, respectively. The correlation coefficients of the
calibration curves were ≥0.992 for parent idebenone
(concentration range tested 0.5–50 ng/ml).
Total idebenone and total metabolites in plasma After
thawing, 180 µL of internal standard (deuterium-labeled
idebenone and deuterium-labeled metabolites in aqueous
NH4OAc buffer; pH 4.6) were added to 200-µL plasma
samples. After deconjugation [incubation at 37°C for 4 h
after adding 20 µl of a glucuronidase/sulfatase-containing
enzyme solution from Helix pomatia (Roche Diagnostics,
Penzberg, Germany)], 200 µl 6 M hydrochloric acid was
added, and the samples were incubated again at 70°C for
30 min. After cooling to room temperature, 1.0 mL ethyl
acetate/hexane (4/1, v/v) was added and the samples were
thoroughly mixed and centrifuged (1,910 g). The resulting
supernatant was separated and evaporated. The residue
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was reconstituted and inserted into the LC-MS/MS
system. Detection was performed after electrospray ioni-
zation (API 365 from MDS Sciex), and the following
transitions were used: for QS10 m/z 353 to 275, for QS6 m/
z 297 to 235, for QS4 m/z 269 to 207. The lower limit of
quantification (LLQ) for total idebenone, total QS10, and
total QS4 in plasma was 50 ng/mL; for total QS6, it was
25 ng/mL. Accuracy and precision for total idebenone
and its metabolites QS10, QS6, and QS4 were 97.7–
101.7% and 5.2–8.0%, respectively. The correlation
coefficients of the calibration curves were ≥0.992 for
total idebenone and all metabolites (concentration range
25–20,000 ng/mL).
Total idebenone and total metabolites in urine Samples
were prepared and inserted into the LC-MS/MS system as
described above. The LLQ was 200 ng/mL for all analytes.
Accuracy and precision were 100.2–109.2% and 2.1–6.8%,
respectively. The calibration range for total idebenone and
metabolites was 200–40,000 ng/ml. The correlation coef-
ficients of the calibration curves were above 0.994 for all
analytes.
Pharmacokinetic analysis
The pharmacokinetic parameters of parent and total
idebenone as well of its metabolites total QS10, total
QS6, and total QS4 in plasma were calculated according to
noncompartmental standard pharmacokinetic methods. As
the plasma concentrations of parent idebenone were very
low, only a limited pharmacokinetic analysis for parent
idebenone was possible. The following parameters were
determined from the plasma concentration-time profile:
area under the curve from time zero to the last sampling
time at which the concentration was at or above the lower
limit of quantification (AUC0−t), maximum plasma concen-
tration observed (Cmax), and time to reach maximum
plasma concentration (tmax).
For total idebenone and its metabolites total QS10, total
QS6, and total QS4, the following parameters were
determined from plasma concentration and urine concen-
tration data: Cmax, tmax, the terminal rate constant (λz;
determined from the terminal slope of the log-transformed
plasma concentration curve using linear regression on
terminal data points using WinNonlin Software, version
5.1, Pharsight, Mountain View, CA, USA), AUC0−t, area
under the plasma concentration-time curve from time zero
to infinity (AUC0–∞; AUC0−t+Clast/λz), area under the
curve within a dosing interval under repeated administra-
tion of idebenone (AUCτ), apparent terminal half-life (t1/2;
calculated as ln2/λz), area under the plasma concentration-
time curve from the last measurement point above the limit
of quantification to infinity (AUCextra), urinary excretion
from time zero to the last urinary collection time after a
single oral administration of idebenone (Ae0−96h), and
urinary excretion within a dosing interval under repeated
administration of idebenone (Aeτ).
If the value for AUCextra provided more than 20% of
AUC0–∞, AUC0–∞ and all values derived from λz were
rejected as implausible and not included in further
statistical analysis. In cases where the actual sampling
time deviated more than 5% in either direction from
scheduled sampling time points, the actual sampling times
were used. Plasma concentrations below the lower limit of
quantification were taken as zero for calculating the AUC.
Plasma concentrations below the lower limit of quantifi-
cation that occurred after the last quantifiable data point
were handled as missing values for calculating λz, Cmax,
and tmax, and were compiled from raw data. The other
pharmacokinetic parameters for total idebenone and for
the total metabolites after single and repeated adminis-
trations were calculated using WinNonlin Software (ver-
sion 5.1). The noncompartmental option was used to
estimate the terminal elimination rate constants and the
area under the plasma concentration-time curve (AUCτ) as
well as AUC0–∞. Urinary excretion of total idebenone and
the metabolites total QS10, total QS6, and total QS4 was
calculated as U × V = Ae, where U = urinary concentra-
tion of the analyte, V = urinary volume per hour, and Ae =
urinary excretion of the analyte per hour. Descriptive
statistics were used to summarize all pharmacokinetic
parameters.
Dose-proportionality of pharmacokinetic data of free
idebenone was assessed by comparing dose-normalized
AUC and Cmax values after first dose and in steady-state
using analysis of variance (SPSS for Windows, version
15.0). Level of significance was P=0.05.
Results
Subjects
Twenty-six subjects were enrolled in the study; 14
subjects were assigned to receive the 150-mg dose of
idebenone (group A) and 12 subjects were assigned to
receive the 750-mg dose (group B). Mean ages and
weights (± SD) of participants were 24.3±4.1 years and
72.0±8.1 kg in group A and 25.8±3.2 years and 74.9±
6.6 kg in group B, respectively. All but one subject
completed the study; this subject discontinued after the
first 150-mg dose of idebenone owing to arterial
hypertension and was not evaluable for pharmacokinetic
parameters. One subject participated in both dosing
groups in the study.
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Pharmacokinetics of idebenone following single
and multiple doses
Main pharmacokinetic parameters Cmax, tmax, and AUC0−t
of parent and total idebenone are shown in Table 1. After
single oral administrations of 150 mg or 750 mg idebenone,
Cmax values of parent idebenone peaked in plasma within
2 h on average and were highly variable. Plasma concen-
trations rarely exceeded the LLQ, indicating that parent
idebenone is rapidly metabolized.
During repeated dosing of both 150 mg three times daily
and 750 mg three times daily, the pre-dose plasma concen-
trations of parent idebenone were below or only slightly
above the lower limit of quantification at both dose levels.
The average Cmax increased 1.2-fold and the average AUC0−t
1.3-fold after repeated dosing of the 150-mg dose, and 1.4-
fold and 1.1-fold, respectively, after repeated dosing of the
750-mg dose, indicating that there was no relevant accumu-
lation of the drug. Cmax and AUC0−t were between 4 and 7
times higher for the 750-mg dose compared to the 150-mg
dose. Dose-normalized values of Cmax and AUC were not
significantly different between the dose groups indicating
approximately linear pharmacokinetics.
Mean plasma concentrations of total idebenone and its
total metabolites after single and repeated dosing are
presented for the 150-mg-dose group (Fig. 2) and 750-mg-
dose group (Fig. 3). Average plasma concentrations were
highest for total idebenone and total QS4 (Tables 1 and 2);
total idebenone reached plasma concentrations 420- to 650-
fold higher than parent idebenone following single and
multiple doses of 150 mg or 750 mg. AUC0−t values of total
idebenone and total QS4 were approximately 1,000 times
higher than AUC0−t values of parent idebenone at both doses
(Table 1). AUC values of total QS10 were approximately
50% of the AUC values of total QS4. Plasma concentrations
of total QS6 were nearly 50% lower than those of total QS10
(Table 2). Similarly to the pharmacokinetic profile of parent
idebenone, there was no clinically relevant accumulation of
total metabolites during repeated dosing, and Cmax and AUC
values increased nearly linearly with dose. The half-lives of
total idebenone and total QS4 tended to increase with
repeated dosing.
Urinary excretion of total metabolites
After single and repeated oral administrations of 150 mg
idebenone, approximately 50% of drug-derived material
was excreted in urine as the conjugated metabolites of QS4
(40%), QS6 (6%), QS10 (<1%), and idebenone (<1%)
(Table 3). At the 750-mg dose, urinary excretion of the
conjugated metabolites amounted to approximately 50% of
QS4, 9% of QS6, 1.5% of QS10, and <1% of idebenone
(Table 3).
Safety and tolerability
After a single oral administration of 150 mg idebenone, 6/14
subjects reported adverse events (AEs) of mild to moderate
Table 1 Pharmacokinetic parameters of pharmacologically active parent idebenone and total idebenone in plasma after single and multiple oral
doses of idebenone
Parent idebenone Total idebenone
PK parameters Cmax (ng/mL) tmax (h) AUC0−t (h·ng/mL) Cmax (ng/mL) tmax (h) AUC0−t (h·ng/mL) t1/2 (h)
150 mg in a single dose
Mean 5.8 0.87 5.5 1,631 1.33 6,277 3.10
SD 4.6 0.55 3.7 516 0.68 2,619 2.29
Range 0.8–16.8 0.33–2.00 0.8–14.6 881–3,003 0.67–3.00 3,510–12,919 1.55–10.05
150 mg given tid for 2 weeks (450 mg total daily dose)
Mean 6.0 0.67 6.0 2,061 1.83 7,322 8.14
SD 6.3 0.19 4.7 868 1.19 3,282 4.64
Range 1.1–22.5 0.33–1.0 1.6–15.2 958–4,173 0.67–5.00 4,248–17,455 2.69–16.72
750 mg in a single dose
Mean 23.6 2.13 37.9 5,229 2.43 32,757 10.80
SD 24.8 1.99 18.0 1,683 1.27 12,296 3.71
Range 5.3–93.7 0.33–6.00 20.6–68.2 2,821–8,784 1.00–5.00 14,481–60,499 4.59–16.87
750 mg given tid for 2 weeks (2,250 mg total daily dose)
Mean 22.4 1.06 39.2 8,158 1.93 32221 15.08
SD 13.5 0.85 19.2 1,978 0.80 10142 4.47
Range 8.1 47.5 0.33–3.0 18.5–81.6 5,320–11,400 1.33–3.50 16,214–46,620 5.31–21.94
Cmax Maximum plasma concentration, tmax time to reach Cmax, AUC0−t area under the plasma drug concentration-time curve from time zero to the
last sampling time at which the concentration was at or above the lower limit of quantification, t1/2 elimination half-life, tid three times daily, SD
standard deviation
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severity. One subject had to be withdrawn from the study after
the very first drug administration because of arterial hyper-
tension. Although it was reported at the screening visit that he
suffered from “white-coat” hypertension, the investigator
judged that the hypertension was probably related to the
study medication. During repeated administration of 150 mg
idebenone, 10/13 subjects reported AEs. Four subjects
reported gastrointestinal AEs and three reported headaches.
The other AEs occurred generally as single events, including
one subject who reported discoloration of the urine. After a
single oral administration of 750 mg idebenone, AEs were
reported in 1/12 subjects (dizziness and migraine). During
repeated administrations of 750 mg idebenone, 11/12 subjects
reported AEs. Discoloration of the urine (n=6), gastrointes-
tinal AEs (n=5), and headache (n=4) were most commonly
reported. There were no clinically relevant changes in
laboratory values, vital signs, or ECG morphology and
QTc-duration at either dose level.
Discussion
Idebenone was quickly absorbed and metabolized in this
population of healthy adult men. There was high inter-
subject variability in plasma concentrations of pharmaco-
logically active parent idebenone after both single and
repeated oral doses of 150 mg tid and 750 mg tid. Due to
the low number of plasma concentrations above the lower
limit of quantification following both single and repeated
doses of idebenone, the apparent elimination half-life
andAUC0–∞ values of parent idebenone could not be
calculated. Total idebenone exhibited linear pharmacoki-
netics over the dose range tested. There was no indication
of accumulation of parent idebenone after repeated doses,
which is consistent with results previously reported for total
idebenone [23, 24].
The idebenone metabolites (QS10, QS6, and QS4)
appeared in the plasma almost synchronously with parent
Fig. 2 Mean plasma concentrations of total idebenone and its total
metabolites after single and repeated oral doses of 150 mg idebenone
in healthy male subjects. a After a single dose and b in steady state
Fig. 3 Mean plasma concentrations of total idebenone and its total
metabolites after single and repeated oral doses of 750 mg idebenone
in healthy male subjects. a After a single dose and b in steady state
498 Eur J Clin Pharmacol (2009) 65:493–501
idebenone, indicating that idebenone was rapidly metabo-
lized, undergoing conjugation and side-chain shortening.
Total idebenone reached plasma concentrations nearly
1,000-fold higher than those of parent idebenone after
single and repeated oral doses at both dose levels; the high
first-pass effect (99%) observed in this study is consistent
with previously published results using lower doses of
idebenone [22]. The Cmax ratios between the 750-mg dose
and the 150-mg dose of idebenone for most of the
metabolites following single and multiple doses were close
to 5, indicating linear pharmacokinetics consistent with
those observed for parent idebenone.
The analysis of the urinary data revealed that total QS4
was the prominent drug-derived material in urine. It
Table 2 Pharmacokinetic parameters of total QS10, total QS6, and total QS4 in plasma after single and multiple oral doses of idebenone
Total QS10 Total QS6 Total QS4
PK parameters Cmax
(ng/mL)
AUC0−t
(h·ng/mL)
t1/2 (h) Cmax
(ng/mL)
AUC0−t
(h·ng/mL)
t1/2 (h) Cmax
(ng/mL)
AUC0−t
(h·ng/mL)
t1/2 (h)
150 mg in a single dose
Mean 744 2576 3.02 258 1889 3.57 1459 5635 3.54
SD 390 1117 1.54 116 776 1.37 632 1046 1.35
Range 285–1462 777–4424 0.72–6.10 111–403 1111–3310 2.30–7.46 667–2355 3559–7086 1.96–7.24
150 mg given tid for 2 weeks (450 mg total daily dose)
Mean 990 3087 5.02 396 1436 3.67 1899 6653 4.28
SD 383 1180 2.90 197 408 1.69 666 1544 1.92
Range 611–1952 2076–6324 1.61–12.74 194–944 895–2293 2.14–8.44 1103–2970 4151–9668 2.52–9.11
750 mg in a single dose
Mean 3932 18725 7.66 1519 8868 5.58 6884 30591 4.15
SD 1455 5566 4.08 492 2463 5.85 3526 7027 2.08
Range 1677–5760 11961–29731 2.03–18.15 882–2593 4739–12105 2.12–23.03 3472–16700 21630–44069 2.24–8.04
750 mg given tid for 2 weeks (2,250 mg total daily dose)
Mean 4387 16300 6.32 1946 8262 4.26 9653 33837 32.49
SD 1267 5204 1.95 532 2626 1.94 1585 5508 18.08
Range 2717–7653 10584–26582 3.95–11.19 1300–3157 5053–12300 2.27–9.22 6886–12760 25524–43930 12.18–78.36
Cmax Maximum plasma concentration, tmax time to reach Cmax, AUC0−t area under the plasma drug concentration-time curve from time zero to the
last sampling time at which the concentration was at or above the lower limit of quantification, t1/2 elimination half-life, tid three times daily, SD
standard deviation
Table 3 Urinary excretion of total idebenone, total QS10, total QS6, and total QS4 in plasma after single and multiple oral doses of idebenone
Urinary excretion (mg) Total idebenone Total QS10 Total QS6 Total QS4
150 mg in a single dose
Mean 0.7 1.4 9.5 68.1
SD 0.3 0.7 3.8 20.6
Range 0.3–1.3 0.5–3.3 5.6–20.6 32.3–116.6
150 mg given tid for 2 weeks (450 mg total daily dose)
Mean 0.8 1.3 8.7 58.8
SD 0.4 0.6 3.5 20.5
Range 0.4–1.6 0.6–2.6 3.3–13.9 20.7–94.6
750 mg in a single dose
Mean 5.6 9.9 56.8 359.2
SD 2.7 3.7 18.6 63.3
Range 2.7–13.2 4.6–15.9 31.2–100.4 266.6–466.1
750 mg given tid for 2 weeks (2,250 mg total daily dose)
Mean 7.1 10.1 65.2 407.4
SD 3.5 4.0 25.4 126.2
Range 3.0–15.5 4.5–17.9 20.7–119.4 187.8–700.9
tid Three times daily, SD standard deviation
Eur J Clin Pharmacol (2009) 65:493–501 499
represented nearly 50% of the drug administered. The
second highest fraction in urine was total QS6. The
percentage of urinary-detectable metabolites also reflected
the water solubility of idebenone as the most lipophilic
compound in this compound group and QS4 as the most
hydrophilic metabolite. Urinary data indicate that a sub-
stantial part of the drug-derived material is excreted by the
kidneys.
Idebenone was generally safe and showed only adverse
events of mild to moderate intensity in this population of
healthy adult males. The most frequently reported adverse
events were gastrointestinal in nature; however, no patient
discontinued from the study as a result of these events. A
dose-dependent increase in the incidence of chromaturia
was observed; this is a known phenomenon likely owing to
the renal excretion of idebenone metabolites [9] and was
also reported in a recent clinical trial that evaluated the
pharmacokinetics and efficacy of idebenone 60 mg kg−1
day−1 given for 1 month [23]. No serious adverse events or
clinically relevant changes in laboratory values, vital signs,
or ECG parameters were noted.
Limitations of this study include the fact that the low
bioavailability of parent idebenone limited the character-
ization of its pharmacokinetic profile, and that there was
high intersubject variability in pharmacokinetic parameters
of parent idebenone. This may make it difficult to
extrapolate these results generally to other populations.
However, results from a recent study in young FA patients
showed an idebenone pharmacokinetic profile similar to
that reported here [23].
In summary, idebenone in daily doses up to 2,250 mg
was safe and well tolerated in healthy adult men. Total
idebenone exhibited linear pharmacokinetics over the dose
range tested. Parent idebenone was subject to a large first-
pass effect, limiting the amount of pharmacologically active
parent idebenone present in the plasma.
Several studies have suggested that idebenone may
improve cardiological symptoms of FA [15–17]. However,
these studies generally used lower doses than those
examined here, and therefore, patients may not have
achieved sufficiently high plasma and subsequently brain
levels of pharmacologically active parent idebenone. As
can be seen in our study, even with comparably high doses,
only low plasma concentrations of idebenone could be
achieved. In previous work, it has been speculated that high
doses of idebenone might be needed to see changes in
neurological symptoms or disease progression of FA [16,
18, 19, 21]. As shown in animal experiments, idebenone
does cross the blood-brain barrier and distributes in brain
tissue, with a significant amount (34%) localized in
mitochondria [25].
Taken together, our results suggest that both efficacy
and safety of higher doses of idebenone need to be
evaluated in controlled clinical trials in patients with FA.
These trials are currently ongoing and should help
determine the appropriate efficacious dose of idebenone
in this population.
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